Matthew Hewitt
Stock Analyst at Craig-Hallum
(2.50)
# 3,056
Out of 5,182 analysts
5
Total ratings
80%
Success rate
12.47%
Average return
Main Sectors:
Stocks Rated by Matthew Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Initiates: Buy | $15 | $10.38 | +44.51% | 1 | Mar 30, 2026 | |
| APYX Apyx Medical | Maintains: Buy | $5 → $6 | $3.76 | +59.57% | 1 | Mar 11, 2026 | |
| CERT Certara | Initiates: Buy | $16 | $6.24 | +156.41% | 1 | Sep 29, 2025 | |
| LFCR Lifecore Biomedical | Maintains: Buy | $8 → $10 | $5.08 | +96.85% | 2 | Nov 22, 2024 |
Cryoport
Mar 30, 2026
Initiates: Buy
Price Target: $15
Current: $10.38
Upside: +44.51%
Apyx Medical
Mar 11, 2026
Maintains: Buy
Price Target: $5 → $6
Current: $3.76
Upside: +59.57%
Certara
Sep 29, 2025
Initiates: Buy
Price Target: $16
Current: $6.24
Upside: +156.41%
Lifecore Biomedical
Nov 22, 2024
Maintains: Buy
Price Target: $8 → $10
Current: $5.08
Upside: +96.85%